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Background: In recent years, virtual reality has been introduced to neurorehabilitation, in particular with the
intention of improving upper-limb training options and facilitating motor function recovery.
Methods/Design: The proposed study incorporates a quantitative part and a qualitative part, termed a mixed-methods
approach: (1) a quantitative investigation of the efficacy of virtual reality training compared to conventional therapy in
upper-limb motor function are investigated, (2a) a qualitative investigation of patients’ experiences and expectations of
virtual reality training and (2b) a qualitative investigation of therapists’ experiences using the virtual reality training
system in the therapy setting. At three participating clinics, 60 patients at least 6 months after stroke onset will be
randomly allocated to an experimental virtual reality group (EG) or to a control group that will receive conventional
physiotherapy or occupational therapy (16 sessions, 45 minutes each, over the course of 4 weeks). Using custom data
gloves, patients’ finger and arm movements will be displayed in real time on a monitor, and they will move and
manipulate objects in various virtual environments. A blinded assessor will test patients’ motor and cognitive
performance twice before, once during, and twice after the 4-week intervention. The primary outcome measure is the
Box and Block Test. Secondary outcome measures are the Chedoke-McMaster Stroke Assessments (hand, arm and
shoulder pain subscales), the Chedoke-McMaster Arm and Hand Activity Inventory, the Line Bisection Test, the Stroke
Impact Scale, the MiniMentalState Examination and the Extended Barthel Index. Semistructured face-to-face interviews
will be conducted with patients in the EG after intervention finalization with a focus on the patients’ expectations and
experiences regarding the virtual reality training. Therapists’ perspectives on virtual reality training will be reviewed in
three focus groups comprising four to six occupational therapists and physiotherapists.
Discussion: The interviews will help to gain a deeper understanding of the phenomena under investigation to provide
sound recommendations for the implementation of the virtual reality training system for routine use in
neurorehabilitation complementing the quantitative clinical assessments.
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Virtual reality (VR)–based training is a fast-developing
field of rehabilitation and has its origins in the gaming
industry. In recent years, VR has been introduced into
neurorehabilitation with the intention of improving
upper-limb training options and facilitating motor func-
tion recovery. Virtual reality is defined as the ‘use of
interactive simulations created with computer hardware
and software to present users with opportunities to en-
gage in environments that appear and feel similar to
real-world objects and events’ [1].
So far, few studies have evaluated the efficacy of VR
training in chronic stroke rehabilitation [2]. In 2011, Laver
et al. analysed 19 randomised controlled trials in their sys-
tematic literature review, which included only seven RCTs
that focused on upper-limb motor function recovery [2].
A meta-analysis of five trials revealed a moderate effect
(Cohen’s d = 0.53) of VR compared to conventional ther-
apy. However, six different commercial or customised VR
training systems were used in the analysed trials. No con-
clusion could be reached regarding the effect of VR train-
ing on grip strength. Furthermore, no recommendations
could be suggested regarding dosage, type or programme
of the VR training.
Over the past few decades, VR technology and its appli-
cations have changed. Besides its potential to trigger
external stimulation, it is hypothesized that VR induces
use-dependent plastic changes in response to internal
stimulation of higher motor cortical areas that recruit the
motor memory system, which consists of stored motor pro-
grams. This so-called VR-based interactive cognitive inter-
vention is based on the idea that stimulation of the action-
processing system in turn activates downstream cortical
areas involved in movement execution. There a population
of neurons—‘mirror neurons’—is purported to play a key
role, as these neurons discharge during both action execu-
tion and action observation or imagery [3]. With the re-
cruitment of a widespread movement network normally
involved in movement execution, VR-based cognitive
therapy offers a potential to specifically promote and/or
enhance functional movement recovery. You et al. demon-
strated important neuroplasticity changes in the primary
sensorimotor cortex after VR training in stroke patients [4].
The observed changes were associated with improved
locomotion.
Other researchers have shown mirror-like visuomotor ac-
tivity in the posterior parietal lobe in humans during
object-related hand actions [5]. Because task-oriented re-
habilitation is known to be beneficial [6], this finding sug-
gests that VR-based cognitive therapy may induce cortical
plasticity and promote recovery by using goal-directed
arm- and hand movements.
It is hypothesized that a system combining two ele-
ments—movement observation with intent to imitateand visualization of mirrored movements of the non-
paretic limb—may optimally induce cortical plasticity
and functional recovery in both acute and chronic
stroke patients. The first element is based on the ob-
servation that mirror neurons discharge during goal-
directed hand actions and also during observation of
another individual performing a similar action. It has
been proposed that mirror neurons constitute a vo-
cabulary of hand actions [7]. Their activation leads to
recruitment of functionally interconnected cortical
structures coupling action execution and observation.
The execution–observation system has also been found
in humans [3]. Moreover, there is evidence that action
observation may facilitate motor activity [3] and
induce cortical plasticity [4]. In addition to action
execution and observation, mirror neurons and motor-
planning areas are known to be activated during volun-
tary motor imagery, which selectively modulates
muscle excitability [4].
In the evaluation of novel technologies developed for
neurorehabilitation, it is important to evaluate efficacy
and the user’s perspective to enhance successful imple-
mentation of the technology. In their literature review,
Laver et al. suggested assessing patients’ motivation, en-
gagement in the therapy and level of enjoyment [2].
Therefore, a mixed-methods approach will be used in the
study proposed here. Together with the randomised effi-
cacy trial it is intended to conduct semistructured patient
interviews and focus group interviews with the treating
therapists. The interviews will help to provide more infor-
mation and a deeper understanding of the phenomena
under investigation to be used in developing sound rec-
ommendations for the implementation of the VR training
system for routine use in neurorehabilitation.
The current study includes two parts: (1) a quantita-
tive investigation of the efficacy of virtual reality train-
ing compared to conventional therapy in upper-limb
motor function are investigated, (2a) a qualitative inves-
tigation of patients’ experiences and expectations of vir-
tual reality training and (2b) a qualitative investigation
of therapists’ experiences using the virtual reality train-
ing system in the therapy setting.Methods and design
This phase III study consists of two parts and envisages
a mixed-methods design comprising quantitative and
qualitative research methods. The research questions,
objectives, hypotheses and methodology of each part
are described separately. Figure 1 illustrates the study
design.
All study parts will conform to the guidelines of good
clinical practice and the Declaration of Helsinki. Ethical
approval was obtained from two responsible Swiss
Figure 1 Study overview. BL, Baseline; conv., Conventional therapy; T0, Preintervention; T1, Measurement after eight treatment sessions; T2,
Measurement event after intervention; FU, Measurement event after 2-month follow-up period; YG, YouGrabber.
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Bern (220/12).
After study implementation, agreed-upon eligibility
criteria or therapy content may limit the progress of the
study. Therefore, each participating centre or therapist
can suggest a modification. However, these modifications
can be employed only if all centres agree to accept and
apply the modifications and if the responsible ethics
committees approve the modifications.
Data collection will be performed in the outpatient
centre of a community hospital, an academic hospital
and a rehabilitation clinic in the German-speaking part
of Switzerland.Part 1: randomised controlled trial
Study design and measurement events
The first part is designed as a randomised, controlled,
assessor-blinded, multicentre trial with two parallel groups
and repeated measurement events (MEs). Patients will be
evaluated by a blinded assessor on five occasions: twice
within 2 weeks at baseline, before intervention start (BL,
T0); once after eight treatment sessions (T1); once imme-
diately after the intervention (T2); and once after a 2-
month follow-up period (FU).
Aim: The aim in the first part is to implement a multi-
centre, single-blind, randomised controlled trial to investi-
gate the efficacy of VR training compared to conventional
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search sites in the German-speaking part of Switzerland
and has two study arms: an experimental group (EG, VR
training) and a control group (CG, conventional therapy).
Research question: The first part is designed to test
the hypothesis that patients after stroke in EG show
higher postintervention performance on the Box and
Block Test (BBT) compared to CG patients.
Hypothesis: It is hypothesised (H0) that there will be
no group differences after 16 training sessions or after
the FU period. It is also hypothesised (H1) that there
will be a group difference after the 16 training sessions
and after the FU period.
Patient selection criteria and recruitment
Patients after stroke will be eligible for study participa-
tion if they fulfil the selection criteria listed in Table 1.
The patient recruitment strategy employs different
approaches:
1. Patients will be recruited from the clinics’
inpatient or outpatient departments by physicians,
therapists and nurses.
2. Patients will be recruited from the clinics’ patient
database. Datasets will be screened for study
selection criteria by the involved study personnel.
If patients are eligible, they will receive a letter
describing the study and including patient
information. If patients are interested in
participating, they can contact the study
personnel in the responsible clinic by telephone,
postal mail or email.
3. Patients will be recruited via a study information
flyer provided on each clinic’s homepage and
through patient self-help groups. If patients areTable 1 Patient selection criteria
Inclusion criteria Exclusion criteria
• ≥6 months after first-ever stroke
(ischaemic, haemorrhagic)
• Previous or current other
functional deficits of arm and
hand motor function not due to
stroke
• Able to sit in a normal chair
without armrests and without
support of the back rest
• Severe cognitive deficits: Mini-
Mental State Examination score
≤20
• Persistent motor deficit of arm
and hand confirmed by Chedoke-
McMaster Stroke Assessment arm
subscale level ≥3 and hand sub-
scale level ≥2 (The difference
between both subscales has to
be two levels or more.)
• Severe visuospatial disorders (for
example, severe visual neglect
confirmed by LineBisectionTest)
• Able to score at least 1 on the Box
and Block Test (main outcome
measure)
• History of epileptic seizures
triggered by visual stimuli (for
example, television, video
games) within the past 6 monthsinterested in participating, they can contact the
study personnel in the responsible clinic by tele-
phone, postal mail or email.
Randomisation and group allocation
After the patient has received written and oral study in-
formation, written informed consent will be obtained
from each patient. The procedure will be performed by
the clinics’ local study coordinator or the blinded asses-
sors before patient inclusion. Documents (patient infor-
mation and consent forms) can be obtained from the
first author. Patients will be randomly allocated to either
the EG or the CG after the second ME (T0). Group allo-
cation will be based on a computer-generated random-
isation list (one for all centres), (MATLAB release
2007b; MathWorks, Natick, MA, USA) created by a re-
searcher not involved in the study. The randomisation
list will be stored at one clinic’s pharmacy. After the sec-
ond ME (T0), the treating therapist will contact the
pharmacist to disclose the group allocation and the
current patient will start with the respective therapy.
Group allocation will remain concealed from the inde-
pendent assessor until study finalisation. Patients and
treating therapists will be reminded not to talk with
other therapists or participants about group allocations.
As the study is single-blind, the treating therapist will
be informed about the patients group allocation. If any
unexpected events (severe or nonsevere) occur, the treat-
ing therapist will inform the physician on duty and the
responsible study organisation personnel to initiate all
necessary procedures.
Assessor blinding
In intervention studies, it is challenging to keep the as-
sessors blinded. To ensure an objective outcome evalu-
ation, the following procedures will be incorporated:
1. Both interventions will take place in the same room.
2. All therapists can apply both interventions.
3. All patients and therapists will be advised not to talk
to the assessor about therapy or training content.
4. Intervention documentation will not be accessible by
the assessor.
5. If in any case blinding is uncovered, either a
different blinded assessor will perform the
assessments or the complete assessment session will
be videotaped to allow for an objective evaluation by
an assessor from a different participating centre.
Study interventions
Both study interventions are described in Table 2 using
the Template for Intervention Description and Replica-
tion checklist and guide, known as TIDieR [8]. Figure 2
shows the training set up for the experimental group.
Table 2 Description of study interventions based on the TIDieR templatea
Item Experimental group Control group
1 Brief name VR training system Conventional therapy
2 Why Both interventions will be compared directly in chronic stroke patients for two reasons:
1.
One-to-one therapy sessions in an adequate amount are limited by health insurance company restrictions.
2.
If VR technology is used, and YG in particular, patients and therapists will want to know if the treatment effect is the same. If yes, YG
could be used to increase the amount of training time with the technology, or it could be recommended as group- or home-based
VR training, which would not be the case if YG performed worse.
3 What:
materials
EG patients will sit in front of the VR system (see Figure 2). They
will wear hand gloves with attached sensors to measure finger
movements of the thumb, index finger, middle finger, wrist
(bending, extending) and lower upper limb (pronation,
supination). Movements will be displayed on the screen in real
time.
No restrictions will be placed on the material used (for example,
ADL material, reaching and grasping material). Use of additional
electrical or mechanical therapy devices (for example, help arm
systems, splints) should be avoided.
4 What:
procedures
The VR system has a variety of training applications for different
movements and at different levels of difficulty. Therapists can
select one of three modes to control the on-screen finger and
arm movements: (1) use of the real arm and/or hand movements,
(2) mirroring of the real movements of one arm and/or hand and
(3) following the movements of one arm and/or hand. The distri-
bution and speed of the appearing objects can be attuned. Fur-
thermore, patients’ movements can be amplified or modulated in
the virtual environment to force decreases or increases in training
difficulty [9]. After the second VR training session, patients should
have tested all training applications and all three modes of finger
and/or hand movements. In the remaining 14 sessions, therapists
will be asked to select at least 3 training applications for each
training session and 2 different movement modes with settings
adapted to each patient’s needs.
The therapy content will focus on a task-related upper-limb treat-
ment in a sitting or lying position. Several manual techniques,




Both study interventions will be provided by experienced physiotherapists or occupational therapists, who will have at least 2 years
of professional experience in the field of neurorehabilitation.
6 How Both study interventions will be conducted individually in one-to-one sessions.
7 Where Both study interventions will take place in the physiotherapy or occupational therapy department of each participating centre.
8 When and
how much
During the 4-week intervention program, patients in both study groups (EG, CG) will receive the same amount of 16 sessions lasting
45 minutes each.
9 Tailoring Training and therapy content will be tailored to each patients preferences, the agreed movement aims and the motor function level
of each patient.
aADL, Activities of daily living; CG, Control group; EG, Experimental group; TIDieR, Template for Intervention Description and Replication checklist and guide; VR,
Virtual reality; YG, YouGrabber. Items 10, 11 and 12 of the TIDieR template do not apply to this study.
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Table 3 provides an overview of all outcome measures
and measurement events. All data will be collected on a
case report form (CRF) that will be stored in a locked
cabinet and will not be accessible by the treating therap-
ist. The standardised CRF can be obtained from the first
author (CSA).
Any patient, who leaves the trial will still be invited to
all planned measurement events so that the recover
process can be followed. The measurement event will in-
clude the same assessments planned for study partici-
pants (Table 3).
Primary outcome: hand dexterity
Change in hand dexterity between T0 and T2 is the pri-
mary outcome of interest. It will be measured with the
BBT, which was described by Mathiowetz et al. in 1985[12]. The test is easy to administer and can be quickly
performed. It has been used in patients after stroke in
patients with multiple sclerosis and traumatic brain in-
jury [13]. Patients will be asked to grasp small wooden
cubes and move them from one side of the box to the
other as fast as possible within 60 seconds. The BBT is a
reliable and valid assessment tool and provides norma-
tive data for healthy individuals in age groups ranging
from 20 years to older than 75. A change of five or six
cubes before and after an intervention seems to be the
smallest real difference [14].
Secondary outcomes: upper-limb activities of daily living
and motor and cognitive function
Upper-limb ADL and motor and cognitive function are
secondary outcomes. They will be assessed objectively
with the Chedoke-McMaster Stroke Assessment (CMSA),
Figure 2 Virtual reality training system setup (YouGrabber). The
model wears hand gloves with movement sensors attached. The
screen displays real-time hand and finger positions.
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and the Line Bisection Test (LBT) and subjectively with
the Stroke Impact Scale (SIS).
The CMSA was developed by Gowland et al. in 1995
for the evaluation of physical impairment and activity
level of stroke patients [15]. In the present study, we will
use the impairment subscales for hand and arm func-
tion. Patients will be scored on a seven-point scale (1 =
hypoactive or absent muscle reflexes, 7 = no functional
impairment detectable anymore, prestroke status) ac-
cording to seven stages of motor recovery [16]. Add-
itionally, shoulder pain of the affected body side will be
evaluated on the same seven-point scale using another
subscale. The CMSA has been shown to be a valid and
reliable assessment tool [15,17].Table 3 Overview of outcome measuresa
Assessment Abbreviation Category
Box and Block Test* BBT Performance m
Chedoke-McMaster Stroke Assessment CMSA Motor impairm
Chedoke McMaster Arm and Hand Activity
Inventory
CAHAI Activity (ADL)
Extended Barthel Index EBI Independence
Edinburgh Handedness Inventory EHI N/A
Mini Mental State Examination MMSE Cognitive asses
Line Bisection Test LBT Neglect assessm
Stroke Impact Scale SIS Impact of strok
communication
*Primary outcome measure. aADL, Activities of daily living; BL, Baseline, FU, Follow-u
vention; T1, After eight intervention sessions; T2, Posttest after 16 intervention sessThe CAHAI was developed by Barreca et al. in 2004
[18-21]. It contains 13 real-life items scored from 1 to 7
(highest score). For example, one item is putting tooth-
paste on a toothbrush. Scores represent the patient’s
relative ability to independently perform stabilisation or
manipulation in ADL with the affected upper limb. A
score of 1 represents total dependence on another per-
son, and a score of 7 indicates patient independence
without time or safety concerns or necessary splints or
devices. The test’s reliability and validity have been eval-
uated [20,21].
The LBT is a paper-and-pencil test used to evaluate
the presence of unilateral spatial neglect (USN) [22]. Pa-
tients are asked to mark the centre of a drawn line on
paper with a pencil. This is repeated for 18 lines on a
sheet of paper. A deviation of more than 6 mm from the
centre in the upper and lower 9 lines indicates the pres-
ence of USN.
The SIS is a questionnaire comprising questions re-
garding the impact of stroke on physical function, emo-
tion, memory, communication and social participation.
The SIS was developed by Duncan and colleagues in
2001 and has been modified in recent years [23]. The
current version, 3.0, consists of eight subscales
(strength, hand function, mobility, ADL, emotion, mem-
ory, communication and participation) comprising a
total of 59 questions that should be administered in a
one-to-one interview. Patients can rate the level of their
stroke’s impact on a 5-point Likert scale. The reliability,
validity and sensitivity to change of this instrument have
been evaluated for version 2.0 [24]. Official translations
have been produced for 14 languages. The higher the
score, the less affected the patient perceives his or her
current status to be. A clinically important difference isMeasurement
events
BL T0 T1 T2 FU
easure X X X X X
ent X X X X X




ent X X X X X
e on ADL, mobility, emotion, memory, strength, X X X X X
p 2 months after study treatment finalisation; N/A, Not applicable; T0, Preinter-
ions.
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the strength, ADL, mobility and hand function sub-
scales, respectively [25].Further assessments and evaluations
At study entry, the MiniMental State Examination [26],
the Edinburgh Handedness Inventory [27] and the Ex-
tended Barthel Index [28] will be used for patient evalu-
ation and descriptive purposes at BL only. Furthermore,
patients’ personal information regarding age, gender,
marital status, education and profession will be re-
corded. All currently received therapy sessions will be
documented by the examiners during BL assessment. If
patients receive another mode of therapy, they will be
asked to reduce or suspend it for the duration of the
study.Sample size and statistical analyses
On the basis of a study on the efficacy of an earlier
study in which the investigators tested the VR system in
children with cerebral palsy [29], a power analysis and
sample size calculation for the present study were per-
formed with G*Power software version 3.1.5 [30]. In the
cited study of children, the BBT (primary outcome
measure) showed an effect size (Cohen’s d) of 0.98. As-
suming a similar effect size for adult stroke patients, we
would need (two-tailed test, power = 0.9, significance
level P-value = 0.05) a total of 46 patients (23 per
group). Assuming a dropout rate of 20%, we will recruit
a total of 60 patients across the participating centres.
Data will be analysed qualitatively and quantitatively
for each patient separately. Changes will be provided as
a total number or percentage. Group comparisons
between EG and CG will be analysed using analysis of
covariance after assessment of normal distribution. We
intend to perform an intention-to-treat analyses. If
necessary, an additional per protocol analysis will be
carried out. Furthermore, subgroup analyses will be per-
formed to investigate any possible study site effects.
Patients’ training settings (nominal and interval data)
will be analysed with frequencies and percentages to de-
scribe therapy content and provide recommendations
for further therapy settings.
All study personnel will try to avoid patient dropouts.
However, patients can leave the study at any time with-
out reason. Collected patient data until the point of
dropout will be included in the final analysis. Missing
data will be replaced using two different approaches: (1)
with the last available value carried forward method and
(2) by adding or subtracting the mean difference of other
patients in the respective group. Analysis with both ap-
proaches will be performed.Part 2
Study design and measurement events
It is highly relevant to consider the patients’ and thera-
pists’ perspectives, in particular if new therapy systems
will be evaluated regarding their effectiveness. Part 2 com-
prises two qualitative investigations to explore patients’
and therapists’ experiences with the VR training system.
The gained knowledge can be used to improve the train-
ing system and to formulate treatment guidelines.
Aim: The aim of the investigations is the exploration
and description of the patients’ and treating therapists’
experiences and expectations during the intervention
with the VR training system. Semistructured interviews
will be conducted with patients in EG and focus groups
will be performed with therapists, who have trained pa-
tients with the VR training system.
Main research question: How do patients and thera-
pists experience the intervention with the VR training
system?
Semistructured interviews with patients
Patients allocated to EG will be offered the opportunity
to participate in one semistructured interview after
intervention finalisation. They will be informed about
and asked for participation during the third or fourth
week of the VR training intervention. The face-to-face
interview will take between 30 to 60 minutes and will be
conducted at the place of the patient’s convenience, ei-
ther at the treating clinic or at the patient’s home. To
provide a high level of privacy, all interviews will take
place in a separate and quiet room. Participation will be
voluntary, and all interviews will be voice-recorded.
A purposive sampling method will be employed ac-
cording to the patients’ experienced phenomenon of
interest [31]. It is proposed to include a sample of about
ten patients to explore and to describe in detail experi-
ences and new knowledge gained in a particular field
[32].
Interview guide semistructured interviews
Semistructured interviews consist of open-ended ques-
tions [33]. The loose structure allows the opportunity to
explore and follow an idea deeper without a preimposed
interview structure [33]. It is intended to provide an in-
depth description of the explored phenomenon [34]. On
the basis of existing literature, an interview guide has
been developed [35]. The guide divides the interview
into three parts (see Additional file 1):
1. Welcoming, information about the interview
procedure, questions regarding the rehabilitation
process and querying the patient’s current condition.
2. Questions regarding the main research question,
such as, What do you think about the VR
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intervention? What were your concerns related to
the training system? How did you experience the
role of the therapist during the VR training?
3. Interview summary by the interviewer, final remarks
of the patient and farewell.
Focus groups with therapists
Therapists treating patients with the VR training system
will be offered the opportunity to participate in a focus
group session that will last from 1 to 2 hours. Therapists
will be informed about and asked for participation after
they have completed at least one series of patient training
with the VR training system, including 16 training sessions
or a comparable number of training sessions with different
patients. The focus group sessions will be conducted at
one of the participating clinics, and three to six therapists
will participate in one focus group. Participation will be
voluntary, and all interviews will be voice-recorded.
Interview guide focus groups
Similar to the semistructured patient interviews, the
focus group questions will be open-ended [33]. The
guide for the focus groups divides the interview into
three parts (see Additional file 2):
1. Welcoming, information about the interview
procedure, introduction of focus group participants
and taking general questions on the VR training
experience.
2. Questions regarding the main research question,
such as, How did you experience the patient during
the VR training? How did you experience the
patient’s motivation? How did you feel during the
training with VR?
3. Interview summary of the interviewer, final remarks
of the participants and farewell.
Semistructured interview and focus group questions
were tested with two patients and therapists beforehand
to check for comprehensibility and clarity and were
reviewed by the responsible ethics committees.
Data analysis of semistructured interviews and focus
groups
In addition to the voice-recording of the interviews and
focus groups, interviewers will write field notes to describe
the interview situation: the way the patient acts during the
interview, the patient’s mood and feelings, the course of
the interview, unexpected events or statements, and the
feelings and impressions of the interviewer. Field notes
and the interview and focus group content will provide
the basis for the data analysis, which will be based on a
descriptive phenomenological approach without data oropinion interpretation [36]. Data analysis will include
three steps:
1. TRANSCRIPTION (step 1): Interview content will
be transcribed verbatim.
2. CONDENSATION (step 2): Patients’ and therapists’
quotes will be summarised to highlight the main
statement.
3. CODING and CATEGORISATION (step 3): On the
basis of the thematic analysis, categories and codes
will be created to sort patients’ and therapists’
statements [37]. This can be done with the help of a
qualitative data analysis tool such as NVivo [38] or
ATLAS.ti [39].
Overall ethical considerations and reporting of adverse
events
The VR training system is a commercial product sold
under the name YouGrabber. It uses VR to train upper-
limb motor function. It has been available (initially as a
beta version) for testing purposes in clinics since 2010
and has been used in rehabilitation institutions and pilot
clinical studies with no safety-related incidents. Never-
theless, patients might experience negative emotions or
have the impression that they cannot perform the train-
ing tasks because of their reduced motor function. It is
expected that study participation will take a lot of pa-
tients’ time in both groups. The following measures will
be utilized in exchange for the patients’ time exposure in
the current study:
 Patients will be assessed on a regular basis to
evaluate their rehabilitation process.
 Patients will have an intensive therapy schedule with
four therapy sessions per week over the course of 4
weeks.
 Patients will have the opportunity to learn about an
innovative VR training system.
 Patients can withdraw from the study at any time
without giving a reason.
The study will be carried out in accordance with the
protocol, with the guidelines for good clinical practice
and current national and international valid legal provi-
sions. Any adverse event will be reported to the respon-
sible ethics committee directly and will be mentioned in
intermediate and final study reports. The study is regis-
tered in the Clinicaltrials.gov trials database with the
identifier NCT01774669.
Quality control and quality assurance
To achieve and maintain a high quality standard during
study preparation and implementation, the following
measures will be employed:
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use the VR training system before study start.
 Comprehensive training for all study therapists to
perform all necessary outcome measures before
study start.
 Three refresher training days for VR system training
and assessment performance throughout the study
 Study management updates for all centres on a
regular basis (monthly).
 Daily telephone and email access for technical
support.
Furthermore, up to three monitoring events will be per-
formed for each participating study centre. An authorised
person from the sponsor, which is not involved in patient
treatment or assessments, will visit the clinics and inspect
data handling and patient organisation. Up to five ran-
domly selected patient data files will be inspected.
All study-related patient data will be entered directly
onto the anonymised case report forms or assessment
scoring sheets. Study-related original patient documents
will remain in the responsible clinic and will be archived
for 10 years. After that period, patient documents will be
destroyed in accordance with the clinic’s data destruc-
tion guidelines. Only anonymised electronic data or
paper copies will be sent to the study coordinator for
data analyses.
Training data collected via the VR training system will
be saved in anonymised form under the patient’s study
ID, with no other identifying information. Data backup
and synchronization will be carried out using a secure,
encrypted data transfer and storage framework.
Dissemination policy
The study personnel will adhere to an open access policy:
 The trialists intend to publish the study protocol
and the study results in international open access
journals to provide easy access to the study
documents for all interested readers.
 The study is registered in an international open
access clinical trial database (Cliniclatrials.gov
Identifier: NCT01774669).
 As the study progresses, its methods and
preliminary results will be presented at national and
international congresses and workshops.
 After study finalisation and data analyses, all study
patients will receive a plain language summary of
the study results, and the results will be presented in
each participating clinic.
Involvement of professional writers is not intended. No
restrictions will be placed on the publication of positive or
negative results. The study results will be reported inaccordance with the guidelines set forth in the 2010 Con-
solidated Standards of Reporting Trials (CONSORT) [40].
Criteria for halting the trial
At present, the commercial YouGrabber system has
been used for more than 2 years with over 100 patients
in different acute hospitals and rehabilitation clinics. So
far, no adverse events have been reported. However, this
study will be halted if any of the following criteria are
fulfilled:
 More than three EG patients report a sudden onset
of or increase in shoulder pain during or just after
therapy that is highly likely to be attributable to the
use of YouGrabber, and which does not immediately
cease after stopping therapy (evaluated as ≤3 on the
Chedoke-McMaster Stroke Assessment subscale
pain).
 More than 50% of EG patients (minimum of five
patients) report severe cybersickness during
YouGrabber training which persists after training is
halted.
 EG patients show an unexpected decrease in motor
function (change of three or more levels in the
Chedoke-McMaster Stroke Assessment) indicating a
highly significant difference between therapies with
YouGrabber compared to conventional therapy.
 Epileptic seizures in at least two patients are
induced directly while using YouGrabber.
Patients reporting the criteria mentioned above will be
evaluated by the physician on duty and will be assessed
and followed up for the originally planned study duration.
Unexpected events
Unexpected events will be categorised as severely unex-
pected events (harmful) and unexpected events (non-
harmful). Each event will be documented on a predefined
form that is available from the first author (CSA) and will
be sent to the overall study coordinator (DK). He will de-
cide if the study insurance provider has to be notified
about the event. All events will be reported to the respon-
sible ethics committee independently from the study in-
surance provider.
Discussion
The aim of this multicentre trial is to determine the effi-
cacy of a VR-based upper-limb training programme
compared to conventional occupational therapy and
physiotherapy. Additionally, the users’ perspectives will
be evaluated by conducting semistructured patient inter-
views and therapist focus groups.
In the rapidly evolving VR training industry, it is im-
portant to develop a detailed perspective on different
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patients’ and therapists’ perceptions. This goal will be
achieved by using a mixed-methods design combining
quantitative and qualitative research methods. In par-
ticular, from the qualitative data, new hypotheses for
further research and adaptations will emerge, including
training recommendations and system modifications.
In addition, the knowledge gained in the present study
will contribute to the trends described in the review by
Laver et al. [2]. On the basis of their systematic review
of the literature reaching back to March 2010 or earlier,
they claimed that the most beneficial patient and VR
system characteristics are still undetermined.
The design of a multicentre study offers several ad-
vantages and challenges. The shared patient recruitment
and treatment methodology provides the opportunity to
conduct a sufficiently powered trial to reduce the risk of
type I error [41]. Also, therapists and patients from vari-
ous clinics and different parts of Switzerland can evalu-
ate the VR training options according to personal
preferences and local conditions.
In the present study, we decided to use only one ran-
domisation list that will be stored in the pharmacy at
one of the three clinics. Therefore, the risk of unblinding
the group allocation is reduced, and patient study entry,
measurement events and treatment sessions will be
under control of one clinic that is responsible for study
management.
The planned study is single-blinded only. In general, a
sham or placebo intervention in therapeutic disciplines
is not always possible. In this study, the treating thera-
pists and patients cannot be blinded to the study group
interventions. However, the assessor and the researchers
performing the data analyses will be blinded to increase
the study’s internal validity and to ensure a low detec-
tion bias [42].
Furthermore, each clinic will assign a responsible
therapist, who will coordinate patient recruitment and
study organisation and conduct therapist training. Regu-
larly scheduled team meetings and study newsletters
will help to ensure employment of homogeneous proce-
dures regarding study management, patient treatment
and communication with the overall study leader and
among all involved clinics.
Trial status
This study is currently recruiting participants. It is antic-
ipated that the trial will take 18 to 36 months for com-
pletion, including all follow-up assessments. The first
patient was randomised in February 2013.
Consent
The authors are thankful to the model in our figure,
who illustrates the equipment of the VR training system.Written informed consent was obtained from the model
for publication of this manuscript and the accompanying
image. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.Additional files
Additional file 1: Interview guide patient interviews.
Additional file 2: Interview guide therapist focus groups.
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